Critères d’évaluation de la TEP au 18F-FDG au cours de l’immunothérapie

Abstract

Checkpoint inhibitor therapy is well established as a first-line treatment for cancer, but assessing treatment response using molecular imaging is still evolving. Evaluating response during checkpoint inhibitor therapy is challenging due to induced immune responses and immune-related adverse effects, which lead to atypical response patterns compared to traditional chemotherapy. Positron emission tomography (PET) and its various radiotracers provide functional information that is valuable for early evaluation of treatment response and can offer critical insights into the efficacy of immunotherapy. Furthermore, PET can help differentiate between patients with a complete response and those with residual disease, potentially guiding clinicians in deciding whether to continue or escalate treatment. This review offers an overview of the application of PET in predicting and evaluating treatment response to immunotherapy, highlighting its potential to refine therapeutic strategies and improve patient outcomes.